- Home
- MRUS vs ACLX Comparison
MRUS vs ACLX Comparison
Compare MRUS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- ACLX
- Stock Information
- Founded
- MRUS 2003
- ACLX 2015
- Country
- MRUS Netherlands
- ACLX United States
- Employees
- MRUS N/A
- ACLX N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- MRUS Health Care
- ACLX Health Care
- Exchange
- MRUS Nasdaq
- ACLX Nasdaq
- Market Cap
- MRUS 5.1B
- ACLX 4.4B
- IPO Year
- MRUS 2016
- ACLX 2022
- Fundamental
- Price
- MRUS $96.19
- ACLX $72.77
- Analyst Decision
- MRUS Buy
- ACLX Strong Buy
- Analyst Count
- MRUS 17
- ACLX 9
- Target Price
- MRUS $94.94
- ACLX $115.50
- AVG Volume (30 Days)
- MRUS 1.3M
- ACLX 912.4K
- Earning Date
- MRUS 10-31-2025
- ACLX 11-05-2025
- Dividend Yield
- MRUS N/A
- ACLX N/A
- EPS Growth
- MRUS N/A
- ACLX N/A
- EPS
- MRUS N/A
- ACLX N/A
- Revenue
- MRUS $56,606,000.00
- ACLX $35,898,000.00
- Revenue This Year
- MRUS $52.81
- ACLX N/A
- Revenue Next Year
- MRUS N/A
- ACLX $220.95
- P/E Ratio
- MRUS N/A
- ACLX N/A
- Revenue Growth
- MRUS 57.54
- ACLX N/A
- 52 Week Low
- MRUS $33.19
- ACLX $47.86
- 52 Week High
- MRUS $96.28
- ACLX $96.39
- Technical
- Relative Strength Index (RSI)
- MRUS 72.69
- ACLX 29.51
- Support Level
- MRUS $95.74
- ACLX $71.05
- Resistance Level
- MRUS $96.18
- ACLX $92.70
- Average True Range (ATR)
- MRUS 0.36
- ACLX 5.10
- MACD
- MRUS -0.39
- ACLX -2.19
- Stochastic Oscillator
- MRUS 89.43
- ACLX 8.52
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.